Pfizer is set to acquire Seagen Inc. for $43 billion in cash. This deal will enable Pfizer to expand its cancer treatment portfolio through Seagen’s expertise in developing biotech drugs that target tumor cells whilst sparing normal tissue using antibody-drug conjugate (ADC) technology. Seagen has four ADC treatments already on the market and a number of promising drugs in development to treat lung and advanced breast cancer. This acquisition presents Pfizer with a substantial opportunity to increase its revenue streams, as cancer treatments are a key focus for the company. The deal is expected to be completed by late 2023 or early 2024 pending regulatory approval and approval from Seagen shareholders.